Revlimid boosts Celgene ahead of Abraxis recognition
This article was originally published in Scrip
Executive Summary
Celgene's revenues leapt by 31% to $910 million in the third quarter and are set to rise further once it begins to recognise revenues from its recently closed acquisition of Abraxis BioScience. The performance beat analysts' expectations owing to better than expected Revlimid (lenalidomide) sales.